GNH USA

Europe — EMA

Modafinilo Aurovitas

GNH USA supplies Modafinilo Aurovitas (Modafinil), a eugeroic for daytime sleepiness in narcolepsy, sleep apnea and shift‑work disorder.

Request sourcing

1
Pack/s

What is Modafinil?

Modafinil, the active ingredient in Modafinilo Aurovitas, is a eugeroic (wakefulness‑promoting agent) presented as an oral tablet for oral use. It is indicated for the treatment of excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder.

GNH USA supplies Modafinilo Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable distribution across multiple regions.

What is Modafinil used for?

Modafinil is a central nervous system stimulant used to improve wakefulness in sleep‑related disorders.

Narcolepsy: reduces excessive daytime sleepiness and improves alertness in patients with narcolepsy. Obstructive sleep apnea (OSA): alleviates residual daytime sleepiness when used alongside standard OSA therapy. Shift work disorder: helps maintain alertness during scheduled work hours for individuals with shift‑work disorder.

What are the side effects of Modafinil?

Common Side Effects: - Headache - Nausea - Insomnia - Dry mouth

Serious or Rare Side Effects: - Severe rash or Stevens‑Johnson syndrome - Psychiatric disturbances such as hallucinations or depression - Cardiovascular events including hypertension or arrhythmia

What precautions apply to Modafinil?

Before initiating therapy, consider the following precautions: - Assess cardiovascular status: evaluate blood pressure and heart rhythm. - Review psychiatric history: avoid in patients with uncontrolled psychosis. - Consider hepatic function: dose may need adjustment in severe liver impairment. - Avoid concomitant use with potent CYP3A4 inhibitors: may increase plasma levels. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

What does Modafinil interact with?

Modafinil may interact with several medicines; careful assessment is required.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can markedly increase modafinil concentrations. - CYP3A4 inducers (e.g., rifampin, carbamazepine): can reduce efficacy by lowering drug levels.

Moderate Interactions (Monitor Closely): - Oral contraceptives: modafinil may reduce hormonal efficacy; consider alternative contraception. - Antidepressants (e.g., SSRIs, SNRIs): may increase risk of serotonin syndrome. - Antihypertensives: modafinil may diminish blood pressure control; monitor blood pressure regularly.

Frequently asked questions

What is Modafinilo Aurovitas used for?+
Modafinilo Aurovitas contains modafinil, a wakefulness‑promoting agent prescribed to reduce excessive daytime sleepiness in conditions such as narcolepsy, obstructive sleep apnea, and shift‑work disorder.
How does modafinil work in the body?+
Modafinil works by inhibiting dopamine reuptake, which raises extracellular dopamine levels, and by activating orexin neurons in the hypothalamus. It also influences histamine, norepinephrine, and serotonin pathways, collectively enhancing alertness and reducing the drive to sleep.
What is the usual dose of Modafinilo Aurovitas?+
The appropriate dose of Modafinilo Aurovitas is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and any relevant safety considerations.
Is Modafinilo Aurovitas safe during pregnancy or breastfeeding?+
Safety data for modafinil in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks before prescribing to pregnant or nursing individuals.
How do I order Modafinilo Aurovitas from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com with the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.
How does Modafinilo Aurovitas compare with other wake‑promoting drugs?+
Modafinil differs from traditional stimulants such as methylphenidate by having a lower risk of cardiovascular stimulation and a longer duration of action. It is often preferred for patients who need sustained wakefulness with fewer sympathomimetic effects.
What are the storage requirements for Modafinilo Aurovitas?+
Store Modafinilo Aurovitas at ambient temperature below 25 °C, in the original packaging, and protect it from moisture and direct sunlight to maintain product stability.
How is Modafinilo Aurovitas administered?+
Modafinilo Aurovitas is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed, unless otherwise directed by a healthcare professional.
What are the most serious risks associated with Modafinilo Aurovitas?+
Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, psychiatric disturbances like hallucinations or depression, and cardiovascular events such as hypertension or arrhythmias. Patients should seek immediate medical attention if any of these occur.
Who should not use Modafinilo Aurovitas?+
Individuals with known hypersensitivity to modafinil, uncontrolled hypertension, severe psychiatric disorders, or those taking contraindicated CYP3A4 inhibitors should avoid using Modafinilo Aurovitas unless advised otherwise by a clinician.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Product details

Drug
Modafinil
Route
Oral Use
Manufacturer
Aurovitas Spain,s.A.U.
Origin
EU

Related products